Sebacia

Duluth, GA, United States
Duluth, GA, United States
SEARCH FILTERS
Time filter
Source Type

"At this pivotal time, we are grateful for the continued support of our top-tier venture capital syndicate and energized by the addition of Salem Partners and other new investors," said Anthony V. Lando, Sebacia's Chief Executive Officer. "From intellectual property to extensive clinical experience and a defined clinical path to approval, we believe we have all the pieces to bring Sebacia's breakthrough treatment for acne to market in Europe and the United States." John Dyett of Salem Partners said, "We have been very impressed by the Sebacia team and are excited to join such a distinguished group of institutional life sciences investors." Sebacia is developing a proprietary microparticle treatment for moderate to severe acne. Sebacia's microparticles are delivered in a topical suspension specifically designed to work with hair removal or pigmented lesion treatment laser systems, which are already owned by the dermatologist. The Sebacia treatment is intended to be a simple, physician-guided, in-office procedure that could provide an alternative to existing therapies, such as oral antibiotics and isotretinoin.  Sebacia has extensive clinical experience with nearly 2,000 treatments performed to date. The procedure is CE Marked in Europe and is being evaluated in clinical studies in the United States. Sebacia intends to use the proceeds from the financing to complete a U.S. pivotal trial with expected results reporting by mid-2018, with submission and FDA response expected by the end of 2018. Further, with CE mark and market clearance for commercialization in Europe, Sebacia also intends to expand its commercial presence in the European Union. Additionally, the company plans to expand its worldwide patent estate, which includes the seminal selective photothermalysis methods developed by Dr. R. Rox Anderson at Massachusetts General Hospital. Made of gold and silica, Sebacia microparticles are specially designed to be activated by the light from commonly used hair removal lasers and are placed in a suspension designed to penetrate the sebaceous follicles. When exposed to a laser pulse, they create a focused photothermal effect in the sebaceous gland and follicle to reduce the activity level of the gland and the inflammatory lesions that cause acne. The Sebacia treatment is being evaluated in clinical studies in the United States and CE Marked in Europe. Sebacia, Inc. is a private medical device company dedicated to creating breakthrough topical therapies for the treatment of dermatological conditions affecting millions of people. Sebacia's goal is to provide a better alternative to the daily use of topical and systemic drugs currently available for the treatment of acne. Sebacia's patented microparticles technology was invented at Rice University, and the proprietary dermatology applications were further developed with researchers from the Wellman Center of Photomedicine at Massachusetts General Hospital. Sebacia is located in Duluth, Georgia. More information is available at www.sebacia.com or follow us at www.twitter.com/SebaciaNews.


Paithankar D.Y.,Sebacia | Sakamoto F.H.,Harvard University | Farinelli W.A.,Harvard University | Kositratna G.,Harvard University | And 15 more authors.
Journal of Investigative Dermatology | Year: 2015

The pathophysiology of acne vulgaris depends on active sebaceous glands, implying that selective destruction of sebaceous glands could be an effective treatment. We hypothesized that light-absorbing microparticles could be delivered into sebaceous glands, enabling local injury by optical pulses. A suspension of topically applied gold-coated silica microparticles exhibiting plasmon resonance with strong absorption at 800 nm was delivered into human pre-auricular and swine sebaceous glands in vivo, using mechanical vibration. After exposure to 10-50 J cm -2, 30 milliseconds, 800 nm diode laser pulses, microscopy revealed preferential thermal injury to sebaceous follicles and glands, consistent with predictions from a computational model. Inflammation was mild; gold particles were not retained in swine skin 1 month after treatment, and uptake in other organs was negligible. Two independent prospective randomized controlled clinical trials were performed for treatment of moderate-to-severe facial acne, using unblinded and blinded assessments of disease severity. Each trial showed clinically and statistically significant improvement of inflammatory acne following three treatments given 1-2 weeks apart. In Trial 2, inflammatory lesions were significantly reduced at 12 weeks (P=0.015) and 16 weeks (P=0.04) compared with sham treatments. Optical microparticles enable selective photothermolysis of sebaceous glands. This appears to be a well-tolerated, effective treatment for acne vulgaris. © 2015 The Society for Investigative Dermatology.


PubMed | Sebacia, New York Laser & Skin Care, Military Institute of Medicine, University of Arkansas at Little Rock and 3 more.
Type: Journal Article | Journal: The Journal of investigative dermatology | Year: 2015

The pathophysiology of acne vulgaris depends on active sebaceous glands, implying that selective destruction of sebaceous glands could be an effective treatment. We hypothesized that light-absorbing microparticles could be delivered into sebaceous glands, enabling local injury by optical pulses. A suspension of topically applied gold-coated silica microparticles exhibiting plasmon resonance with strong absorption at 800nm was delivered into human pre-auricular and swine sebaceous glands in vivo, using mechanical vibration. After exposure to 10-50Jcm(-2), 30 milliseconds, 800nm diode laser pulses, microscopy revealed preferential thermal injury to sebaceous follicles and glands, consistent with predictions from a computational model. Inflammation was mild; gold particles were not retained in swine skin 1 month after treatment, and uptake in other organs was negligible. Two independent prospective randomized controlled clinical trials were performed for treatment of moderate-to-severe facial acne, using unblinded and blinded assessments of disease severity. Each trial showed clinically and statistically significant improvement of inflammatory acne following three treatments given 1-2 weeks apart. In Trial 2, inflammatory lesions were significantly reduced at 12 weeks (P=0.015) and 16 weeks (P=0.04) compared with sham treatments. Optical microparticles enable selective photothermolysis of sebaceous glands. This appears to be a well-tolerated, effective treatment for acne vulgaris.

Loading Sebacia collaborators
Loading Sebacia collaborators